Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors by Bazarov, Alexey V & Yaswen, Paul
Introduction
Five major breast cancer subtypes – basal, luminal A, 
luminal B, ERBB2-positive, and normal breast-like – are 
distinguishable on the basis of molecular proﬁ  ling [1]. 
Both luminal A and luminal B subtypes are estrogen 
receptor (ER)-positive, but luminal B tumors are more 
metastatic [2] and have poorer prognoses [3]. Each of the 
breast cancer subtypes is characterized by a speciﬁ  c 
pattern of genomic abnormalities [4]. Luminal B tumors 
often contain high-level ampliﬁ  cations of chromosome 
region 8p12, and patients bearing tumors with ampli  ﬁ    ca-
tions in this region exhibit signiﬁ  cantly poorer outcomes 
than patients whose tumors do not contain such ampli-
ﬁ  cations [4]. Th   e most commonly ampliﬁ  ed 1 Mb seg  ment 
in the 8p12 region contains only ﬁ   ve genes for which 
ampliﬁ   cation correlates with the gene expression: 
ZNF703, ERLIN2, PROSC, BRF2, and RAB11FIP1 [5,6]. 
Until now, however, the identity of the driver oncogene 
within this group remained elusive.
Articles
Two recent reports describe high-density array compara-
tive genomic hybridization analyses of the 8p12 region 
using independent panels of breast tumors and cell lines 
[6,7]. In one case, 1,001 primary breast cancers were used 
to deﬁ  ne the boundaries of the minimal amplicon [6]. 
Both sets of these comparative genomic hybridization 
results implicate ZNF703 as the main gene whose 
ampliﬁ  cation is selected for in luminal B cancers. Th  e 
evidence includes two tumors in which ZNF703 was the 
only gene ampliﬁ  ed within the 8p12 region. High levels of 
ZNF703 ampliﬁ     cation and mRNA expression were 
associated with poor outcomes in ER-positive and 
luminal tumors.
Th  e association studies are supplemented by experi-
men  tal data obtained using cell culture models. Transfec-
tion of ZNF703 resulted in transformation of NIH 3T3 
cells, and induced proliferation of both nonmalignant 
human mammary epithelial cells and malignant MCF7 
cells. Holland and coworkers [6] further demonstrated 
that increased levels of ZNF703 resulted in decreased 
expres  sion of transforming growth factor beta (TGFβ) 
receptor II and prevented TGFβ from inhibiting pro-
lifera  tion of MCF7 cells. Binding of ZNF703 to the TGFβ 
receptor II promoter was demonstrated by chromatin 
immuno  precipitation, and was associated with repressive 
chromatin modiﬁ  cations. ZNF703 contains a single zinc 
ﬁ  nger domain and is unlikely to bind to DNA directly, 
however [8]. Sircoulomb and colleagues [7] found that 
ZNF703 forms complexes with DCAF7, PBH2, and 
NCOR2 factors involved in transcriptional repression, in 
agreement with the proposed function of the ZNF703 
homolog Nlz1 in zebraﬁ  sh development [9].
While the ZNF703 promoter contains estrogen-
respon  sive elements and its expression is responsive to 
estrogen, ZNF703 transfection led to reduced ER expres-
sion and activity in MCF7 cells, indicating the existence 
of negative feedback regulation [7]. ZNF703 transfection, 
however, also resulted in reduced expression of cell cycle 
inhibitors p27 and p15, increased pRb phosphorylation, 
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© 2011 BioMed Central Ltdand increased E2F1 transcriptional activity. Based on 
these data, the authors of this work propose that ZNF703 
expression leads to a shift from an ER-regulated to an 
E2F1-regu  lated transcriptional program, characteristic of 
luminal B tumors. Additional data indicate that ZNF703 
expression leads to activation of pathways involved in 
stem cell self-renewal, and that it increases the ratio of 
luminal to basal progenitors, suggesting that, in addition 
to promoting proliferation, its oncogenic function 
includes altering diﬀ  erentiation kinetics.
Th  e new ﬁ  ndings in human tissues and cells comple-
ment another recent study showing that Zeppo1 (Zpo1), 
the murine homolog of ZNF703, reduces cell–cell adhe-
sion and increases invasiveness as well as proliferation in 
three-dimensional cultures [10]. At the molecular level, 
Zeppo1 represses E-cadherin expression and causes 
increased expression of the promigratory p120-catenin 
isoform. Consequently, Zeppo1 overexpression promotes 
metastasis in a murine tumor model. Th   ese results may 
explain invasiveness and poor prognosis in human 
luminal B tumors.
Viewpoint
While ZNF703 has been largely unknown in the breast 
cancer ﬁ   eld, the new reports ﬁ   rmly establish it as a 
functional contributor to luminal B tumors. Th  e  prepon-
derance of clinical correlations and experimental data are 
commensurate with the classical deﬁ  nition of an onco-
gene. As elegantly pointed out [7], however, the oncogene 
concept is evolving and expanding to accommodate 
context-dependent genetic and epigenetic features, as 
well as novel functions. For example, while ZNF703 
transfection by itself can cause anchorage-independent 
growth of NIH 3T3 cells – a classical demonstration of 
oncogenicity – it does not cause transformation of 
MCF10A cells unless p53 is also compromised [11]. 
Under normal circumstances, aberrant proliferation is 
insuﬃ   cient for malignancy. Regulation of proliferation, 
however, is intimately connected to diﬀ  erentiation. Th  e 
major oncogenic role of ampliﬁ  ed/overexpressed ZNF703 
may be dysregulation of diﬀ  erentiation rather than abro-
gation of cell cycle checkpoints.
Now that ZNF703 has been ﬁ  rmly implicated in the 
pathogenesis of luminal B breast cancers, the next 
challenges will be to determine how expression/function 
of the encoded protein can be regulated and to determine 
the major downstream eﬀ  ectors of its oncogenic func-
tions. For example, cyclin D1, located at chromosome 
11q13, induces ZNF703 expression in an E2F1-dependent 
fashion [11]. As ZNF703 is in turn involved in E2F 
signaling, these results may explain frequent coampliﬁ  -
cations of 8p12 and 11q13 regions. By mapping ZNF703 
connections to other biochemical pathways, it may be 
possible to ﬁ   nd pharmacologically tractable points at 
which the eﬀ  ects  of  ZNF703  ampliﬁ   cation might be 
mitigated.
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